Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.
The atypical antipsychotic drug olanzapine has been proposed for treatment of dopaminergic psychosis in Parkinson's disease (PD). We report on a 68-year-old patient who developed a severe akinetic-rigid extrapyramidal syndrome, accompanied by additional paranoid symptoms, following olanzapine treatment of optic hallucinosis in PD. Olanzapine may also induce clinically relevant extrapyramidal side effects in PD patients.
Rudolf
J
J
Klinik für Neurologie, Universität zu Köln, Germany.
Ghaemi
M
M
Schmülling
S
S
D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects*; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001480:Basal Ganglia Diseases / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis; D001569:Benzodiazepines; D003024:Clozapine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006212:Hallucinations / Q000139:chemically induced* / Q000188:drug therapy*; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D008297:Male; D000077152:Olanzapine; D010259:Paranoid Disorders / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy*; D010880:Piperidines / Q000009:adverse effects*; D010890:Pirenzepine / Q000009:adverse effects / Q000031:analogs & derivatives*; D012642:Selegiline / Q000009:adverse effects*; D012720:Severity of Illness Index
D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D010880:Piperidines; D001569:Benzodiazepines; D012642:Selegiline; D010890:Pirenzepine; D007980:Levodopa; D003024:Clozapine; C026710:budipine; D000077152:Olanzapine